Accessibility Menu
Arrow-Thin-Down
S&P 500
6,812.61
+0.7%
+46.73
Arrow-Thin-Down
DJI
47,427.12
+0.7%
+314.67
Arrow-Thin-Down
NASDAQ
23,214.69
+0.8%
+189.10
Arrow-Thin-Down
Bitcoin
$90,245.00
+3.5%
+$3,052.72
Arrow-Thin-Down
AAPL
$277.82
+0.3%
+$0.85
Arrow-Thin-Down
AMZN
$229.29
-0.2%
-$0.38
Arrow-Thin-Down
GOOG
$320.54
-1.0%
-$3.10
Arrow-Thin-Down
META
$633.61
-0.4%
-$2.61
Arrow-Thin-Down
MSFT
$485.50
+1.8%
+$8.51
Arrow-Thin-Down
NVDA
$180.34
+1.4%
+$2.52
Arrow-Thin-Down
TSLA
$426.72
+1.7%
+$7.32
Daily Stock GainersDaily Stock LosersMost Active Stocks
Finch Therapeutics Group Stock Quote

Finch Therapeutics Group (OTC: FNCH)

$13.51
(-3.5%)
-0.48
Price as of November 26, 2025, 11:48 a.m. ET

KEY DATA POINTS

Current Price
$13.51
Daily Change
(-3.5%) $0.48
Day's Range
$13.51 - $13.51
Previous Close
$13.51
Open
$13.51
Beta
0.56
Volume
116
Average Volume
2,287
Sector
Health Care
Market Cap
22.5M
Market Cap / Employee
$13.99M
52wk Range
$10.15 - $15.85
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
$0.00
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Finch Therapeutics Group Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
FNCH+13.91%N/AN/A-98%
S&P+13%+86.41%+13.26%+73%

Finch Therapeutics Group Company Info

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Somerville, MA.

News & Analysis

Featured Article

Why Finch Therapeutics Stock Is Skyrocketing Today

The FDA, at long last, has lifted a clinical hold on Finch's C. diff program.

Keith Speights  |  Apr 29, 2022

Financial Health

General

Q2 2024YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.04M0.0%
Market Cap$2.20M0.0%
Market Cap / Employee$2.20M0.0%
Employees10.0%
Net Income-$4.83M0.0%
EBITDA-$6.07M0.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2024YOY Change
Net Cash$16.04M0.0%
Accounts Receivable$0.00M0.0%
Inventory00.0%

Liabilities

Q2 2024YOY Change
Long Term Debt$26.90M0.0%
Short Term Debt$2.09M0.0%

Ratios

Q2 2024YOY Change
Return On Assets-25.20%0.0%
Return On Invested Capital-61.24%0.0%

Cash Flow

Q2 2024YOY Change
Free Cash Flow-$4.73M0.0%
Operating Free Cash Flow-$4.73M0.0%

Valuation

MetricQ4 2023Q1 2024Q2 2024YoY Change
Price to Book0.220.180.12-
Price to Sales54.18-
Price to Tangible Book Value0.220.180.12-
Enterprise Value to EBITDA-2.33-2.53-2.50-
Return on Equity-128.7%-62.6%-67.3%-
Total Debt$30.13M$29.56M$28.99M-

No results found

No podcast episodes available.

No results found

No transcripts available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services